source
- Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchApnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.Fierce Biotech · 5h ago↗ source
- Alnylam shares tumble nearly 30% after cutting revenue outlook for key amyloidosis drugsAlnylam Pharmaceuticals saw its market value drop about 30%, roughly $12 billion, after it lowered its revenue forecast for its leading amyloidosis treatments. The company had previously expected…